Experimental One-Dose Treatment Cuts 'Bad' Cholesterol by 52% in First Human Trial
Reported byScienceAlert ↗·Sourced by Goodlede
CTX310, a CRISPR-based gene therapy delivered intravenously, reduced LDL cholesterol by an average of 52.5% and triglycerides by 47.8% in a 12-month follow-up of 14 participants who received the highest dose, with sustained results and no new serious adverse events reported.
This is a small early trial of 15 participants; further development and larger clinical trials are needed before the treatment becomes available to patients.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at ScienceAlert
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede